Physician profile
Qaiser Niaz
NPI 1528056389
$14,748.56
in general payments reported to CMS, 2019-2025
77 companies · $4,090 in 2025
The $4,090 reported for 2025 was more than what 79% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,265 · 2020: $769 · 2021: $1,080 · 2022: $984 · 2023: $2,530 · 2024: $4,031 · 2025: $4,090.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Education: $62.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,588.36 |
| Education | $62.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $1,184.55 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Astrazeneca Pharmaceuticals LP | $1,100.43 | 2019-2025 | Enhertu, Calquence, Lynparza |
| Janssen Biotech, INC. | $1,087.53 | 2019-2025 | Darzalex, Rybrevant, Carvykti |
| Novartis Pharmaceuticals Corporation | $1,064.30 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $932.47 | 2019-2025 | Opdivo |
| Pfizer INC. | $910.50 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $699.64 | 2019-2025 | Fruzaqla, Ninlaro, Iclusig |
| Celgene Corporation | $676.96 | 2019-2025 | Reblozyl |
| Astellas Pharma US INC | $609.29 | 2019-2025 | Xtandi, Vyloy, Xospata |
| Eisai INC. | $427.32 | 2019-2025 | |
| Amgen INC. | $390.97 | 2020-2024 | Evenity, Prolia, Xgeva |
| Glaxosmithkline, LLC. | $336.45 | 2021-2025 | Jemperli, Zejula, Ojjaara |
| Abbvie INC. | $313.52 | 2021-2025 | |
| Seagen INC. | $275.39 | 2019-2023 | Adcetris |
| Genentech USA, INC. | $262.29 | 2019-2025 | Venclexta, Itovebi, Polivy |
Show all 77 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $230.27 | 2019-2025 | Verzenio, Jaypirca |
| Daiichi Sankyo INC. | $218.25 | 2019-2025 | Enhertu, Datroway, Injectafer |
| Pharmacyclics LLC, An Abbvie Company | $210.30 | 2021-2023 | Imbruvica, Epkinly |
| Springworks Therapeutics, INC. | $185.62 | 2024-2025 | Ogsiveo |
| Coherus Oncology, INC. | $182.47 | 2023-2025 | Loqtorzi |
| Kite Pharma, INC. | $178.73 | 2021-2025 | Yescarta |
| Incyte Corporation | $160.16 | 2021-2025 | Monjuvi, Niktimvo, Jakafi |
| Array Biopharma INC | $159.19 | 2019-2025 | Mektovi, Braftovi, Lorbrena |
| Pharmacosmos Therapeutics INC. | $151.96 | 2023-2025 | Monoferric |
| Genzyme Corporation | $140.86 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $136.71 | 2024-2025 | Libtayo |
| Stemline Therapeutics INC. | $134.66 | 2023-2025 | Orserdu, Elzonris |
| Bayer Healthcare Pharmaceuticals INC. | $126.84 | 2019-2025 | |
| Agios Pharmaceuticals, INC. | $122.02 | 2025 | Pyrukynd |
| Puma Biotechnology, INC. | $106.24 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $101.95 | 2020-2025 | |
| Acrotech Biopharma INC. | $99.73 | 2021-2025 | Beleodaq |
| US Oncology Corporate, INC. | $98.57 | 2024 | |
| Tempus Ai, INC | $92.90 | 2024-2025 | Xt Cdx |
| Progenics Pharmaceuticals, INC. | $85.81 | 2024 | |
| Janssen Pharmaceuticals, INC | $73.72 | 2020-2024 | Xarelto |
| Sobi, INC | $71.02 | 2022-2024 | |
| Rigel Pharmaceuticals, INC. | $70.72 | 2023-2025 | Rezlidhia, Tavalisse, Tavalisse |
| Tersera Therapeutics LLC | $70.03 | 2024-2025 | Zoladex, Quzyttir |
| Caris Mpi, INC. | $61.71 | 2025 | Mi Cancer Seek |
| Taiho Oncology, INC. | $57.87 | 2020-2024 | |
| Sumitomo Pharma America, INC. | $53.30 | 2023 | Orgovyx |
| Alexion Pharmaceuticals, INC. | $53.10 | 2019-2025 | Ultomiris |
| Kyowa Kirin, INC. | $51.22 | 2021-2025 | |
| Cti Biopharma Corp. | $49.79 | 2023 | Vonjo |
| Myriad Genetic Laboratories, INC. | $49.46 | 2023 | Precisetumor |
| Foundation Medicine, INC. | $44.93 | 2023 | |
| Dexcom, INC. | $44.83 | 2022-2023 | Dexcom G6 Transmitter |
| Spectrum Pharmaceuticals INC. | $44.29 | 2025 | Rolvedon |
| Gilead Sciences, INC. | $39.68 | 2019-2023 | |
| Jazz Pharmaceuticals INC. | $39.08 | 2019-2020 | |
| Novo Nordisk INC | $37.54 | 2021-2022 | |
| Mylan Institutional INC. | $35.87 | 2023 | Fulphila, Ogivri |
| Servier Pharmaceuticals LLC | $35.72 | 2024-2025 | |
| Dendreon Pharmaceuticals LLC | $34.27 | 2022 | |
| Syndax Pharmaceuticals, INC. | $32.73 | 2025 | |
| Emd Serono, INC. | $31.33 | 2021-2024 | |
| Octapharma USA, INC. | $30.00 | 2023 | Octagam Immune Globulin (Human) |
| Geron Corporation | $29.73 | 2025 | Rytelo |
| Legend Biotech USA INC. | $29.44 | 2025 | Carvykti |
| Tesaro, INC. | $28.04 | 2019 | |
| Fresenius Kabi USA, LLC | $27.98 | 2025 | Stimufend |
| Pharmaessentia USA Corporation | $27.31 | 2025 | Besremi |
| Aveo Pharmaceuticals, INC. | $27.00 | 2024 | |
| Apellis Pharmaceuticals, INC. | $26.45 | 2023 | |
| Global Blood Therapeutics, INC. | $24.29 | 2021 | |
| Verastem, INC. | $24.28 | 2019 | |
| Immunogen, INC. | $24.02 | 2023 | Elahere |
| Genmab U.S., INC. | $23.54 | 2024 | Epkinly |
| Dova Pharmaceuticals | $22.75 | 2019 | |
| Verity Pharmaceuticals INC. | $22.06 | 2025 | Trelstar |
| Myovant Sciences INC. | $19.68 | 2021 | |
| Beigene USA, INC. | $18.96 | 2021 | |
| Heron Therapeutics, INC. | $18.46 | 2021 | |
| Clovis Oncology, INC. | $17.86 | 2019 | |
| Fennec Pharmaceuticals, INC. | $16.09 | 2025 | Fyarro |
| Medtronic, INC. | $13.56 | 2023 | Synchromedii |
Drugs and devices associated with these payments
Keytruda $898Opdivo $558Reblozyl $527Imbruvica $447Enhertu $365Lynparza $365Lenvima $347Darzalex $317Kisqali $298Epkinly $271Tukysa $257Jemperli $242Xtandi $242Zejula $213Ibrance $206Calquence $197Scemblix $189Fruzaqla $188Ninlaro $169Yescarta $161Ogsiveo $154Monoferric $152Padcev $147Mektovi $142Braftovi $142Imfinzi $139Libtayo $137Verzenio $133Rybrevant $129Carvykti $129Udenyca $126Iclusig $123Pyrukynd $122Lorbrena $119Welireg $118Adcetris $105Elrexfio $104Pluvicto $92.63Tagrisso $92.35Orserdu $89.25Vonjo $88.15Monjuvi $87.28Pylarify $85.81Vyloy $83.93Orgovyx $83.15Mekinist $81.98Xospata $81.24Fabhalta $79.11Xt Cdx $75.76Rezlidhia $70.72Tavalisse $70.72Evenity $65.70Prolia $65.70Ayvakit $64.12Mi Cancer Seek $61.71Keytruda Qlex $60.92Venclexta $59.88Promacta $59.49Loqtorzi $56.81Jaypirca $56.51Nerlynx $54.28Sarclisa $54.11Tecvayli $53.90Xalkori $53.71Jakafi $52.52Niktimvo $52.52Precisetumor $49.46Vectibix $47.55Xgeva $47.55Nplate $47.55Erleada $46.86Zoladex $46.41Ojjaara $45.89Elzonris $45.41Piqray $45.12Rolvedon $44.29Datroway $44.28Xofigo $43.44Inqovi $42.73Lonsurf $42.73Talzenna $39.43Inlyta $39.43Fulphila $35.87Ogivri $35.87Tibsovo $35.72Xarelto $34.25Akeega $33.39Balversa $33.39Ultomiris $33.14Itovebi $30.60Octagam Immune Globulin (Human) $30.00Rytelo $29.73Poteligeo $28.39Tasigna $28.18Stimufend $27.98Besremi $27.31Fotivda $27.00Polivy $25.47Beleodaq $24.51Elahere $24.02
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Qaiser Niaz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.